You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Acute and late toxicity

From: Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity

  Grade 1–2 Grade 3 Grade 4
Acute (≤ 3 months post-treatment) toxicity incidence in N = 37 patients
NONE N = 11 (30%)
 Diarrhoea N = 5 (14%) 0 0
 Nausea N = 8 (22%) 0 0
 Vomiting N = 2 (5%) 0 0
 Dyspepsia N = 2 (5%) 0 0
 Anorexia N = 2 (5%) 0 0
 Pain N = 7 (19%) N = 1 (3%) 0
 Fatigue N = 11 (30%) N = 1 (3%) 0
 Jaundice N = 1 (3%) 0 0
 Obstructive Jaundice 0 N = 1 (3%) 0
Late (>  3 months post-treatment) toxicity incidence in N = 32
NONE N = 27 (84%)
 Pain N = 1 (3%)* 0 0
 Nausea N = 1 (3%)* 0 0
 Pancreatic Insufficiency N = 1 (3%) 0 0
 GI Bleeding 0 0 N = 2 (6%)
 Duodenal Stricture 0 0 N = 2 (6%)
  1. *one patient experienced Grade 2 pain and Grade 2 nausea